Liquidia's Revenue Soars on Product Sales, Net Loss Narrows

Ticker: LQDA · Form: 10-Q · Filed: Nov 3, 2025

Sentiment: mixed

Topics: Biopharmaceutical, Pulmonary Hypertension, YUTREPIA, Commercialization, Litigation Risk, Revenue Growth, Debt Increase

Related Tickers: LQDA, UTHR

TL;DR

**LQDA is finally generating significant product revenue, but watch those rising debt levels and SG&A costs closely; it's a high-stakes bet on YUTREPIA's market penetration.**

AI Summary

Liquidia Corp (LQDA) reported a significant increase in total revenue to $54.342 million for the three months ended September 30, 2025, up from $4.448 million in the same period of 2024, primarily driven by $51.669 million in product sales, which were zero in the prior year. Despite this revenue growth, the company posted a net loss of $3.533 million for the quarter, a substantial improvement from the $31.030 million net loss in Q3 2024. For the nine months ended September 30, 2025, total revenue reached $66.299 million, compared to $11.079 million in 2024, with a net loss of $83.479 million, an improvement from the $89.781 million loss in the prior nine-month period. Selling, general and administrative expenses surged to $40.056 million in Q3 2025 from $20.182 million in Q3 2024, reflecting increased commercialization efforts for YUTREPIA. Research and development expenses decreased to $9.346 million in Q3 2025 from $11.890 million in Q3 2024. The company's cash and cash equivalents decreased to $157.496 million as of September 30, 2025, from $176.479 million at December 31, 2024, while long-term debt (current and noncurrent) increased significantly to $192.497 million from $113.284 million over the same period.

Why It Matters

Liquidia's dramatic shift to product sales, primarily YUTREPIA, signals a critical transition from a development-stage company to a commercial entity, which is vital for investor confidence and future profitability. The substantial increase in selling, general and administrative expenses indicates aggressive market penetration strategies, which could challenge competitors like United Therapeutics. For employees, this commercialization success could mean job security and growth opportunities. Customers, particularly patients with pulmonary hypertension, stand to benefit from increased access to new treatment options, potentially improving quality of life and treatment efficacy. The broader market will watch to see if Liquidia can sustain this revenue growth and achieve profitability, potentially influencing valuations for other biopharmaceutical companies in similar stages.

Risk Assessment

Risk Level: high — The company's long-term debt has significantly increased from $113.284 million at December 31, 2024, to $192.497 million at September 30, 2025, indicating higher financial leverage. Additionally, the ongoing litigation with United Therapeutics, where remedies sought include the removal of YUTREPIA from the market, poses a substantial existential risk to Liquidia's primary revenue driver. The accumulated deficit of $640.868 million as of September 30, 2025, also highlights a history of losses.

Analyst Insight

Investors should closely monitor Liquidia's YUTREPIA sales trajectory and the progress of its litigation with United Therapeutics. While revenue growth is promising, the increased debt and high SG&A expenses demand scrutiny. Consider a 'wait and see' approach until there's more clarity on the legal outcome and sustained profitability.

Financial Highlights

debt To Equity
11.51
revenue
$54.342M
operating Margin
3.25%
total Assets
$275.981M
total Debt
$192.497M
net Income
-$3.533M
eps
N/A
gross Margin
N/A
cash Position
$157.496M
revenue Growth
+1118.3%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$51.669MN/A
Service Revenue$2.673M-39.9%

Key Numbers

Key Players & Entities

FAQ

What were Liquidia Corp's key financial results for the third quarter of 2025?

Liquidia Corp reported total revenue of $54.342 million for the three months ended September 30, 2025, a significant increase from $4.448 million in Q3 2024. The company's net loss for the quarter was $3.533 million, an improvement from a $31.030 million net loss in the prior year's quarter.

How did Liquidia's product sales contribute to its revenue in Q3 2025?

Product sales, primarily from YUTREPIA, were the main driver of Liquidia's revenue growth, totaling $51.669 million in Q3 2025. This marks a substantial change as product sales were zero in the comparable period of 2024, indicating successful commercialization efforts.

What is the status of Liquidia's litigation with United Therapeutics?

Liquidia is involved in ongoing patent litigation with United Therapeutics in the U.S. District Court for the District of Delaware and the U.S. District Court for the Middle District of North Carolina. United Therapeutics is seeking remedies that include the removal of YUTREPIA from the market, posing a significant risk to Liquidia's commercial operations.

What are the trends in Liquidia's expenses for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Liquidia's total costs and expenses increased to $137.462 million from $96.266 million in the prior year. Selling, general and administrative expenses saw a substantial rise to $108.942 million from $60.374 million, reflecting increased commercialization activities, while research and development expenses decreased to $22.333 million from $31.367 million.

How has Liquidia's debt position changed as of September 30, 2025?

Liquidia's total long-term debt (current and noncurrent) increased significantly to $192.497 million as of September 30, 2025, from $113.284 million at December 31, 2024. This increase is primarily due to proceeds from long-term debt, net of fees, totaling $74.975 million during the nine-month period.

What is YUTREPIA and why is it important to Liquidia?

YUTREPIA is a key product for Liquidia, representing its primary source of product sales revenue. It is a drug product administered using Plastiape's RS00 Model 8 dry powder inhaler, and its successful commercialization is central to Liquidia's strategy to transition from a development-stage company to a profitable biopharmaceutical firm.

What is Liquidia's cash position as of September 30, 2025?

As of September 30, 2025, Liquidia's cash and cash equivalents stood at $157.496 million, a decrease from $176.479 million at December 31, 2024. The net cash used in operating activities for the nine months ended September 30, 2025, was $79.930 million.

What are the main risks Liquidia faces according to the 10-Q filing?

Key risks include the ongoing patent litigation with United Therapeutics, which could lead to YUTREPIA's removal from the market, and the ability to maintain regulatory approvals for its products. Other risks involve the ability to develop and commercialize product candidates, establish manufacturing arrangements, and manage increased debt levels.

How has Liquidia's stock-based compensation changed in 2025?

Stock-based compensation expense for Liquidia increased to $22.266 million for the nine months ended September 30, 2025, compared to $13.777 million for the same period in 2024. This reflects an increase in non-cash compensation to employees and executives.

What is Liquidia's strategic outlook regarding its product pipeline?

Liquidia plans to continue developing and commercializing its product candidates, including YUTREPIA, and expanding its label for new indications. The company is also working on L606 and developing medical devices for drug administration, such as a nebulizer for L606 and an infusion pump with Sandoz for generic treprostinil injection.

Risk Factors

Industry Context

Liquidia operates in the biopharmaceutical industry, focusing on developing treatments for rare pulmonary diseases. The sector is characterized by high R&D costs, long development cycles, stringent regulatory oversight from bodies like the FDA, and significant competitive pressures from established players and emerging biotech firms. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Regulatory Implications

The company's commercialization efforts for YUTREPIA are subject to FDA regulations and post-market surveillance. Any adverse events or manufacturing issues could lead to regulatory scrutiny, product recalls, or delays, impacting revenue and reputation. Compliance with pharmaceutical marketing and sales regulations is also critical.

What Investors Should Do

  1. Monitor SG&A expense trajectory
  2. Analyze debt utilization and repayment strategy
  3. Evaluate product sales growth sustainability
  4. Assess cash burn rate relative to cash reserves

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, which stood at $640.868M as of September 30, 2025.)
Product Sales, net
Revenue generated from the sale of the company's manufactured or acquired products, after accounting for returns, allowances, and discounts. (This is a new and significant revenue driver for Liquidia in Q3 2025, contributing $51.669M.)
Selling, general and administrative expenses (SG&A)
Costs incurred by a company for marketing, advertising, sales, and administrative functions, excluding research and development. (These expenses surged to $40.056M in Q3 2025, reflecting increased commercialization efforts.)
Long-term debt, current
The portion of long-term debt obligations that are due within one year. (This component of debt increased significantly to $56.051M as of September 30, 2025.)
Long-term debt, noncurrent
The portion of long-term debt obligations that are due in more than one year. (This component of debt increased significantly to $136.446M as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Liquidia Corp has experienced a dramatic transformation in its revenue profile, with total revenue soaring from $4.448M in Q3 2024 to $54.342M in Q3 2025, primarily due to the introduction of product sales. Despite this revenue surge, the company's net loss has narrowed significantly from $31.030M to $3.533M, indicating improved operational efficiency relative to revenue. However, this growth has been accompanied by a substantial increase in SG&A expenses, more than doubling to $40.056M, and a significant rise in total long-term debt to $192.497M, while cash reserves have seen a modest decline.

Filing Stats: 4,443 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-11-03 07:00:26

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Financial Statements (unaudited) 6 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 6 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 8 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 9 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 47 Item 1A.

Risk Factors

Risk Factors 47 Item 5. Other Information 96 Item 6. Exhibits 96

Signatures

Signatures 97 This Quarterly Report on Form 10-Q, includes our trademarks, trade names and service marks, such as Liquidia, the Liquidia logo, YUTREPIA and PRINT, which are protected under applicable intellectual property laws and are the property of Liquidia Technologies, Inc. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 2 Table of Contents Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. We intend such forward-looking statements to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The forward-looking statements are contained principally in the sections entitled "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements Liquidia Corporation Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 157,496 $ 176,479 Accounts receivable, net 35,959 2,719 Inventory 24,534 241 Prepaid expenses and other current assets 8,730 5,666 Total current assets 226,719 185,105 Property, plant and equipment, net 10,704 8,298 Operating lease right-of-use assets, net 4,014 4,187 Indemnification asset, related party 8,294 7,460 Contract acquisition costs, net 6,901 7,286 Intangible asset, net 2,988 3,156 Goodwill 3,903 3,903 Restricted cash 3,504 — Other assets 8,954 10,918 Total assets $ 275,981 $ 230,313 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 6,019 $ 4,689 Accrued expenses and other current liabilities 40,444 18,659 Long-term debt, current 56,051 18,016 Operating and finance lease liabilities, current 428 417 Total current liabilities 102,942 41,781 Litigation finance payable 8,284 7,300 Long-term debt, noncurrent 136,446 95,268 Operating and finance lease liabilities, noncurrent 6,257 6,586 Total liabilities 253,929 150,935 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock — 10,000,000 shares authorized, none outstanding — — Common stock — $ 0.001 par value, 115,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively, 86,819,212 and 84,683,063 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 87 85 Additional paid-in capital 662,833 636,682 Accumulated deficit ( 640,868 ) ( 557,389 ) Total stockholders' equity 22,052 79,378 Total liabilities and stockholders' equity $ 275,981 $ 230,313 The accompanying notes are an integral part

View on Read The Filing